Paper665309
Changes in plasma volume and extracellular fluid volume and after addition of hydralazine to propranolol treatment in patients with hypertension.
Ibsen H and 3 others. Acta Med Scand, 1978. Cited by 32 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Changes in plasma volume and extracellular fluid volume and after addition of hydralazine to propranolol treatment in patients with hypertension. Papers, record 665309. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/665309
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Changes in plasma volume and extracellular fluid volume and after addition of hydralazine to propranolol treatment in patients with hypertension.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Extracellular Space | Major topic |
| Hydralazine | Major topic |
| Hypertension | Major topic |
| Plasma Volume | Major topic |
| Propranolol | Major topic |
| Adult | |
| Aged | |
| Drug Evaluation | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Male | |
| Middle Aged |
Source PubMed
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 6,653,652 | Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension. | Eur J Clin Pharmacol | 1983 | https://conductscience.org/library/papers/6653652 | PubMed |
| 6,124,423 | Long-term therapy of arterial hypertension with nifedipine given alone or in combination with a beta-adrenoceptor blocking agent. | Eur J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/6124423 | PubMed |
| 2,905,154 | Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group. | Br J Clin Pharmacol | 1988 | https://conductscience.org/library/papers/2905154 | PubMed |
| 2,876,898 | Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy. | Eur J Clin Pharmacol | 1986 | https://conductscience.org/library/papers/2876898 | PubMed |
| 2,487,529 | Comparison of indapamide and hydrochlorothiazide plus amiloride as a third drug in the treatment of arterial hypertension. | Cardiovasc Drugs Ther | 1989 | https://conductscience.org/library/papers/2487529 | PubMed |
| 1,981,681 | The efficacy and tolerability of long-term felodipine treatment in hypertension. The Scandinavian Multicenter Group. | Cardiovasc Drugs Ther | 1990 | https://conductscience.org/library/papers/1981681 | PubMed |
| 1,981,020 | Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy. | Cardiovasc Drugs Ther | 1990 | https://conductscience.org/library/papers/1981020 | PubMed |
| 520,398 | Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension. | Eur J Clin Pharmacol | 1979 | https://conductscience.org/library/papers/520398 | PubMed |
| 477,707 | Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension. | Eur J Clin Pharmacol | 1979 | https://conductscience.org/library/papers/477707 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/665309
GET https://conductscience.org/api/papers/v1/665309/authors